重症筋無力症:パイプラインレビュー2019下半期

【英語タイトル】Myasthenia Gravis - Pipeline Review, H2 2019

Global Markets Directが出版した調査資料(GDATA9120326)・商品コード:GDATA9120326
・発行会社(調査会社):Global Markets Direct
・発行日:2019年11月
・ページ数:181
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール(受注後24時間以内)
・調査対象地域:グローバル
・産業分野:製薬及び医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,000 ⇒換算¥218,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD4,000 ⇒換算¥436,000見積依頼/購入/質問フォーム
Enterprisewide Price(複数事業所内共有可)USD6,000 ⇒換算¥654,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Myasthenia Gravis – Pipeline Review, H2 2019
Summary

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Myasthenia Gravis – Pipeline Review, H2 2019, provides an overview of the Myasthenia Gravis (Immunology) pipeline landscape.

Myasthenia gravis is autoimmune neuromuscular disease characterized by weakness and rapid fatigue of any of the muscles under voluntary control. Symptoms include drooping of one or both eyelids, diplopia and difficulty swallowing, chewing and speaking. Treatment includes immunosuppressants, corticosteroids and surgery.

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Myasthenia Gravis – Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Myasthenia Gravis (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Myasthenia Gravis (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Myasthenia Gravis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 6, 6, 5, 16, 2 and 1 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 1 molecules, respectively.

Myasthenia Gravis (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Myasthenia Gravis (Immunology).
- The pipeline guide reviews pipeline therapeutics for Myasthenia Gravis (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Myasthenia Gravis (Immunology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Myasthenia Gravis (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Myasthenia Gravis (Immunology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Myasthenia Gravis (Immunology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Myasthenia Gravis (Immunology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Myasthenia Gravis – Overview
Myasthenia Gravis – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Myasthenia Gravis – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Myasthenia Gravis – Companies Involved in Therapeutics Development
Ahead Therapeutics SL
Akari Therapeutics Plc
Alexion Pharmaceuticals Inc
Alpha Cancer Technologies Inc
Argenx SE
BioMarin Pharmaceutical Inc
Bristol-Myers Squibb Co
Cabaletta Bio Inc
CuraVac Inc
Grifols SA
HanAll Biopharma Co Ltd
Kashiv BioSciences LLC
Momenta Pharmaceuticals Inc
Neurotune AG
Novartis AG
Pfizer Inc
Protalex Inc
Ra Pharmaceuticals Inc
Toleranzia AB
Tolerion Inc
UCB SA
Viela Bio Inc
Myasthenia Gravis – Drug Profiles
abatacept – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ACT-101 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
amifampridine phosphate – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AT-1616 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
batoclimab – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Biologic to Agonize Aryl Hydrocarbon Receptor for Myasthenia Gravis – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
bortezomib – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CVMG-01 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Descartes-08 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
efgartigimod alfa – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy for Myasthenia Gravis – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HBN-1 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HBN-100 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
immune globulin (human) – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
inebilizumab – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
iscalimab – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
K-127 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KIMS-002 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KPL-045 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KPL-404 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
methotrexate – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
nipocalimab – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
nomacopan – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NPO-15 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NT-1654 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
orilanolimab – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PF-06755347 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PRTX-100 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ravulizumab – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Proteins to Inhibit Complement C5 for Myasthenia Gravis – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rozanolixizumab – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit Complement C5 for Autoimmune Disorders, Atypical Hemolytic Uremic Syndrome, Central Nervous System and Paroxysmal Nocturnal Hemoglobinuria – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TOL-1 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TOL-2 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TOL-3034 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine for Myasthenia Gravis – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
zilucoplan – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
zilucoplan XR – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Myasthenia Gravis – Dormant Projects
Myasthenia Gravis – Discontinued Products
Myasthenia Gravis – Product Development Milestones
Featured News & Press Releases
Oct 07, 2019: Cabaletta Bio announces presentation of preclinical data showing specific CAAR T activity against Anti-MuSK expressing B Cells
Oct 02, 2019: Ra Pharmaceuticals announces dosing of first patient in global phase 3 pivotal study of Zilucoplan for gMG
Sep 04, 2019: Ra Pharmaceuticals receives Orphan Drug Designation from the U.S. FDA for Zilucoplan for the Treatment of Myasthenia Gravis
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Myasthenia Gravis, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Products under Development by Universities/Institutes, H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Myasthenia Gravis - Pipeline by Ahead Therapeutics SL, H2 2019
Myasthenia Gravis - Pipeline by Akari Therapeutics Plc, H2 2019
Myasthenia Gravis - Pipeline by Alexion Pharmaceuticals Inc, H2 2019
Myasthenia Gravis - Pipeline by Alpha Cancer Technologies Inc, H2 2019
Myasthenia Gravis - Pipeline by Argenx SE, H2 2019
Myasthenia Gravis - Pipeline by BioMarin Pharmaceutical Inc, H2 2019
Myasthenia Gravis - Pipeline by Bristol-Myers Squibb Co, H2 2019
Myasthenia Gravis - Pipeline by Cabaletta Bio Inc, H2 2019
Myasthenia Gravis - Pipeline by CuraVac Inc, H2 2019
Myasthenia Gravis - Pipeline by Grifols SA, H2 2019
Myasthenia Gravis - Pipeline by HanAll Biopharma Co Ltd, H2 2019
Myasthenia Gravis - Pipeline by Kashiv BioSciences LLC, H2 2019
Myasthenia Gravis - Pipeline by Momenta Pharmaceuticals Inc, H2 2019
Myasthenia Gravis - Pipeline by Neurotune AG, H2 2019
Myasthenia Gravis - Pipeline by Novartis AG, H2 2019
Myasthenia Gravis - Pipeline by Pfizer Inc, H2 2019
Myasthenia Gravis - Pipeline by Protalex Inc, H2 2019
Myasthenia Gravis - Pipeline by Ra Pharmaceuticals Inc, H2 2019
Myasthenia Gravis - Pipeline by Toleranzia AB, H2 2019
Myasthenia Gravis - Pipeline by Tolerion Inc, H2 2019
Myasthenia Gravis - Pipeline by UCB SA, H2 2019
Myasthenia Gravis - Pipeline by Viela Bio Inc, H2 2019
Myasthenia Gravis - Dormant Projects, H2 2019
Myasthenia Gravis - Discontinued Products, H2 2019

List of Figures
Number of Products under Development for Myasthenia Gravis, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Number of Products by Top 10 Targets, H2 2019
Number of Products by Stage and Top 10 Targets, H2 2019
Number of Products by Top 10 Mechanism of Actions, H2 2019
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019

【掲載企業】

Ahead Therapeutics SL
Akari Therapeutics Plc
Alexion Pharmaceuticals Inc
Alpha Cancer Technologies Inc
Argenx SE
BioMarin Pharmaceutical Inc
Bristol-Myers Squibb Co
Cabaletta Bio Inc
CuraVac Inc
Grifols SA
HanAll Biopharma Co Ltd
Kashiv BioSciences LLC
Momenta Pharmaceuticals Inc
Neurotune AG
Novartis AG
Pfizer Inc
Protalex Inc
Ra Pharmaceuticals Inc
Toleranzia AB
Tolerion Inc
UCB SA
Viela Bio Inc

★調査レポート[重症筋無力症:パイプラインレビュー2019下半期] (コード:GDATA9120326)販売に関する免責事項を必ずご確認ください。
★調査レポート[重症筋無力症:パイプラインレビュー2019下半期]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆